



## Summary of Changes Report – October 2008

### Menopause and Hormone Therapy (HT): Collaborative Decision-Making and Management

---

#### Annotations

- \*2c) More text and updated verbiage was added to this annotation to further support the conclusion that long-term estrogen use may precipitate coronary heart disease and estrogen given in early menopause may prevent atherosclerosis. Literature added: *Rossouw, 2007; Grodstein, 2006; Manson, 2007.*

Text was added to state that recent retrospective studies suggest that in younger women who have undergone oophorectomy, a protective benefit of hormone therapy may be seen. Literature added: *RoCCA, 2007; RoCCA, 2008.*

- \*3) Added text regarding micronized progesterone and medroxyprogesterone. It appears that they do not have any increased thrombogenic risk. *Canonico, 2007.*

#### Appendix E

A warning from the FDA regarding the use of bioidentical hormones was added.

#### Priority Aims & Suggested Measures, Measurement Specifications

None

#### Support for Implementation

Key Implementation Recommendations were added.

*\*An asterisk indicates any changes in clinical practice recommendations*